Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Myelofibrosis (MF) · Chronic Myelomonocytic Leukemia (CMML)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Naveen Pemmaraju, MD) · npemmaraju@mdanderson.org · 713-792-4956
Contact: Principal Investigator (Naveen Pemmaraju, MD)

Study leads

Naveen Pemmaraju, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis · Primary Myelofibrosis · Post-PV MF

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Canton, United States

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

Abroad (travel likely)RecruitingPHASE3

Chengdu, China · Tianjin, China

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis · Post-PV MF · Post-ET Myelofibrosis

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Gilbert, United States

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelofibrosis; Anemia · Anemia · Myelofibrosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gilbert, United States · Duarte, United States